Boston Scientific Corp annual free cash flow for fiscal TTM was $3.4 billion, a decrease of 5.9% from $3.7 billion in fiscal 2025. All figures are reported results from public filings — no estimates or projections.
| Free Cash Flow (annual) | TTM → 2026-03-31 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $3.4B | $3.7B | $2.6B | $1.7B | $914M | $1.3B | $1.1B | $1.4B | ($6M) | $1.1B | $596M | $353M | $1.0B | $837M | $1.0B | $704M | $47M | $473M | $854M | $571M | $1.5B |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Free Cash Flow (quarterly) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
|---|---|---|---|---|---|---|---|---|
| Free Cash Flow (FCF) | $171M | $1.0B | $1.2B | $1.1B | $354M | $1.2B | $698M | $658M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
More BSX metrics: Revenue · Gross Profit · Operating Income · Net Income · EPS · EBITDA · Shares Outstanding
All BSX financial statements → Interactive BSX charts →
About TickerBase · Data methodology & sources